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Abstract
Background: A difficult problem in treating opioid addicts is the maintenance of a drug-free state because of the negative 
emotional symptoms associated with withdrawal, which may trigger relapse. Several lines of evidence suggest a role for the 
metabotropic glutamate receptor 5 in opioid addiction; however, its involvement during opioid withdrawal is not clear.
Methods: Mice were treated with a 7-day escalating-dose morphine administration paradigm. Following withdrawal, the 
development of affective behaviors was assessed using the 3-chambered box, open-field, elevated plus-maze and forced-
swim tests. Metabotropic glutamate receptor 5 autoradiographic binding was performed in mouse brains undergoing chronic 
morphine treatment and 7  days withdrawal. Moreover, since there is evidence showing direct effects of opioid drugs on 
the metabotropic glutamate receptor 5 system, the presence of an metabotropic glutamate receptor 5/μ-opioid receptor 
interaction was assessed by performing metabotropic glutamate receptor 5 autoradiographic binding in brains of mice 
lacking the μ-opioid receptor gene.
Results: Withdrawal from chronic morphine administration induced anxiety-like, depressive-like, and impaired sociability 
behaviors concomitant with a marked upregulation of metabotropic glutamate receptor 5 binding. Administration of the 
metabotropic glutamate receptor 5 antagonist, 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine, reversed morphine abstinence-induced 
depressive-like behaviors. A brain region-specific increase in metabotropic glutamate receptor 5 binding was observed in the 
nucleus accumbens shell, thalamus, hypothalamus, and amygdala of μ-opioid receptor knockout mice compared with controls.
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Conclusions: These results suggest an association between metabotropic glutamate receptor 5 alterations and the emergence 
of opioid withdrawal-related affective behaviors. This study supports metabotropic glutamate receptor 5 system as a target 
for the development of pharmacotherapies for the treatment of opioid addiction. Moreover, our data show direct effects of 
μ-opioid receptor system manipulation on metabotropic glutamate receptor 5 binding in the brain.
Keywords: Morphine, withdrawal, μ-opioid receptor, mGlu5R, opioids
Introduction
Opioid addiction is a relapsing brain disorder characterized 
by compulsion to seek and take the drug, despite the negative 
physical and emotional consequences following abstinence (Le 
Moal and Koob, 2007). Symptoms associated with affective emo-
tional impairment, including anxiety, depression, stress, and 
anhedonia, during drug withdrawal act as a motivational trigger 
to relapse (Martin and Jasinski, 1969; Jaffe, 1990; Nunes et  al., 
2004; Peles et  al., 2007), which is the primary problem for the 
treatment of opioid addiction (Stotts et al., 2009). In fact, there 
is 30% to 40% comorbidity between substance use disorders 
and illicit drug abuse with major depression (Davis et al., 2008). 
Addressing the mechanisms underlying the emotional impair-
ment associated with opioid abstinence is essential given this 
high comorbidity prevalence, along with the ambiguous efficacy 
of classic antidepressant treatment in this patient population 
(Nunes et al., 2004).
While opioid drugs, including morphine and heroin, pri-
marily act on the μ-opioid receptor (MOPr) to exert their 
neurochemical and behavioral effects (Matthes et  al., 1996), 
evidence also suggests a role for the glutamatergic system to 
underlie several opioid addiction processes (Kalivas, 2009). 
A role for metabotropic glutamate receptor 5 (mGlu5R) in drug 
self-administration as well as reinstatement of drug-seeking 
behavior has been reported (Gass and Olive, 2008). With respect 
to opioids, pharmacological blockade of the mGlu5R attenuated 
the development of tolerance to morphine (Kozela et al., 2003; 
Gabra et al., 2008), inhibited the expression of morphine loco-
motor sensitisation (Kotlinska and Bochenski, 2007), prevented 
the acquisition (Roohi et al., 2014) and expression of morphine 
place-preference (Popik and Wrobel, 2002; Aoki et  al., 2004; 
Herzig and Schmidt, 2004; Veeneman et al., 2011), and decreased 
morphine self-administration (Brown et al., 2012) in rodents. In 
addition, administration of the mGlu5R antagonist, 3-((2-Methyl-
4-thiazolyl)ethynyl)pyridine (MTEP), decreased cue-induced 
reinstatement of morphine seeking in mice (Brown et al., 2012), 
and intra-nucleus accumbens shell (AcbSh) administration 
of the mGlu5R antagonist 2-Methyl-6-(phenylethynyl)pyridine 
(MPEP) decreased heroin-seeking induced by context, cues, or 
heroin priming in rats (Lou et al., 2014). Moreover, mGlu5R antag-
onism has been found to potentiate the antinociceptive effects 
of morphine in rats (Picker et al., 2011). However, the role of the 
mGlu5R on the modulation of morphine withdrawal-induced 
emotional impairment has not yet been investigated.
Therefore, in the present study, we first aimed to characterize 
the behavioral/emotional consequences of morphine withdrawal 
and investigate the effects of chronic morphine administration 
and withdrawal on mGlu5R binding in the brain of mice. We 
found that morphine abstinence induced anxiety-like, depres-
sive-like, and impaired sociability behaviors concomitant with a 
marked region-specific upregulation of mGlu5R binding, possibly 
suggesting the presence of MOPr-mGlu5R interaction in the brain. 
We also assessed the effects of mGlu5R antagonism on the rever-
sal of morphine withdrawal-induced depressive-like behaviors 
to directly explore the possible involvement of central mGlu5R 
system in the emotional component of morphine withdrawal. To 
further assess the effects of MOPr system manipulation on the 
mGlu5R system, we performed mGlu5R autoradiographic binding 
in brains of mice lacking the MOPr gene (MOPr knockout mice). 
Our findings provide further evidence for a key role of the cen-
tral mGlu5R system in the modulation of the emotional conse-
quences of opioid abstinence and suggest the existence of an 
mGlu5R-MOPr interaction to be localized in the nucleus accum-
bens, thalamus, hypothalamus, and amygdala, regions highly 
associated with reward and emotions.
Methods
Animals
Chronic Morphine and Withdrawal Experiments—Male C57BL/6J 
mice (7 weeks old, 20–25 g, Charles River Laboratories, Kingston, 
UK) were housed individually in a temperature-controlled envi-
ronment with a 12-hour-light/-dark cycle (lights on 6:00 am). Food 
and water were available ad libitum. Mice acclimatized in their 
new environment for at least 7  days prior to experiments and 
were handled daily. All experimental procedures were conducted 
in accordance with the UK Animal Scientific Procedures Act (1986).
Mu Opioid Receptor Knockout Study—The brains from 
8-week-old MOPr knockout mice were provided by Professor 
Brigitte Kieffer’s laboratory (IGBMC, Strasbourg, France). The 
experimental methodology for the generation of MOPr knockout 
mice used in the current study has been previously described 
elsewhere (Matthes et al., 1996).
Chronic “Intermittent” Escalating-Dose Morphine 
Administration Paradigm and Withdrawal
Mice were randomly divided into chronic saline- and morphine-
treated groups (n = 6/group). Mice were injected (i.p.) with saline 
(4 mL/kg) or morphine-HCl (Sigma-Aldrich, Poole, UK) with a 
chronic, “intermittent” escalating-dose administration paradigm 
(20 mg/kg on day 1, 40 mg/kg on days 2 and 3, 80 mg/kg on days 
4 and 5, and 100 mg/kg on days 6 and 7)  twice per day at 9:00 
am and 5:00 pm in accordance with previously published pro-
tocols (Muller and Unterwald, 2004; Zhou et al., 2006; Goeldner 
et al., 2011; Zanos et al., 2014). Both groups of animals were left to 
spontaneously withdraw in their home cages without injections. 
Different cohorts of mice were assessed for withdrawal-associ-
ated affective behaviors and mGlu5R binding. Body weight was 
measured daily.
Characterization of a Mouse Model of Opioid 
Withdrawal
To characterize the behavioral effects of morphine withdrawal, 
mice were treated with 7  days of escalating-dose morphine 
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paradigm and spontaneous withdrawal for a period of 6 to 
8  days. Mice were tested for sociability (6  days withdrawal; 
Crawley’s 3-chambered social approach test), anxiety-like 
behavior (7 days withdrawal; open-field and elevated-plus maze 
[EPM] tests), and depression-like behaviors (8 days withdrawal; 
forced-swim test [FST]). The order of testing was determined by 
the degree of stress-inducing properties of each test, with the 
least stressful conducted first and the most potentially distress-
ing test last (Clemens et al., 2007). The Crawley’s 3-chambered 
social approach test, EPM, and FST were performed as previously 
described (Zanos et al., 2014) (see supplementary Materials and 
Methods). To further assess opioid abstinence-associated anx-
iety-related behaviors, mice were placed in open-field arenas 
(40 cm x 20 cm x 20 cm) 7 days following the last treatment injec-
tion, and time spent in the center of the arena was scored for 
10 minutes by a trained observer blind to the treatment groups. 
Twenty-four hours following the last behavioral test (ie, FST), 
mice were euthanized by 30-second exposure to CO2 followed by 
decapitation and spleen was weighed for peripheral assessment 
of stress (Kyo et  al., 1999; Dominguez-Gerpe and Rey-Mendez, 
2001).
To assess the role of mGlu5R on morphine withdrawal-
induced depressive-like behaviors, we used a different cohort 
of mice undergoing the same morphine administration and 
withdrawal paradigm as described above. On day 8 (24 hours fol-
lowing a 15-minute FST pretest) of withdrawal, we administered 
saline (vehicle) or MTEP (3 mg/kg, i.p.), and 30 minutes later we 
assessed for depressive-like behaviors in the FST, as described 
by Zanos et al. (2014). Dose and timing of administration of MTEP 
was determined based on previous studies assessing the effects 
of MTEP in the FST paradigm (Palucha et al., 2005; Belozertseva 
et al., 2007; Pomierny-Chamiolo et al., 2010; Domin et al., 2014).
Autoradiographic Binding of mGlu5R in the Brain 
of Mice
A separate cohort of mice underwent the same administra-
tion paradigm for biochemical assessments. For this cohort of 
animals, mice were not assessed in any other behavioral test. 
One hour following the final morphine/saline injection for the 
chronic administration group and 7 days postfinal injection for 
the withdrawal groups, mice were euthanized by 30-second 
exposure to CO2 followed by decapitation and brains were col-
lected and immediately frozen in isopentane solution (-25oC). 
Coronal brain sections were cut (20  μm thick; 300  μm apart) 
using a cryostat (Zeiss Microm 505E, Hertfordshire, UK), thaw-
mounted onto gelatin subbed ice-cold microscope slides, and 
processed for autoradiography as described previously (Kitchen 
et al., 1997).
Quantitative mGlu5R autoradiography was performed in 
brain sections of all treatment groups and both genotypes as 
described previously (Georgiou et al., 2015; Wright et al., 2015). 
For the determination of total binding, slides were incubated 
for 60 minutes in 10 nM [3H]-MPEP (American Radiolabeled 
Chemical, 2.22 TBq/mmol) in Tris-HCl buffer (pH 7.4, 4oC). 
Adjacent brain section were incubated with [3H]-MPEP (10 nM) in 
the presence of 10 μM fenobam (Tocris Bioscience, Bristol, UK) to 
determine the nonspecific binding.
Slides with radioligand bound sections were apposed to 
films (Kodak BioMax MR-1  films; Sigma-Aldrich, Gillingham, 
UK) for 3 weeks along with appropriate 3H microscale stand-
ards (Amersham Pharmacia Biotech) to allow quantification. 
Films were then developed and analyzed in parallel in a com-
plete paired protocol as described by Kitchen et  al. (1997). All 
structures were identified by reference to the mouse brain atlas 
of Franklin & Paxinos (2007) and analyzed using an image ana-
lyzer (MCID; Image Research, Linton, UK).
Statistical Analysis
All the values are expressed as mean ± SEM. The effects of mor-
phine withdrawal on anxiety-like and depressive-like behav-
iors were analyzed by Student’s t test. For analysis of sociability 
deficits, 2-way repeated-measures ANOVA was performed with 
factors “treatment” and “chamber (ie, empty and stranger – 
repeated factor).” The effects of morphine administration and 
withdrawal on spleen weight were analyzed by 2-way ANOVA for 
factors “treatment” (ie, saline and morphine) and “experimen-
tal phase” (ie, chronic and withdrawal). For analysis of mGlu5R 
autoradiographic binding following chronic morphine adminis-
tration and withdrawal, 2-way ANOVA with factors “treatment” 
(ie, saline and morphine) and “experimental phase” (ie, chronic 
and withdrawal) was performed in each brain region. The effects 
of MTEP pretreatment on depressive-like behaviors in the FST 
were assessed using 2-way ANOVA for factors “pretreatment” 
(ie, saline and MTEP) and “treatment” (ie, saline and morphine). 
For assessing the effects of MOPr gene deletion on mGlu5R bind-
ing, unpaired Student’s t test was used in each individual region. 
For the regression analysis, Pearson correlation coefficient test 
was performed. ANOVAs were followed by a Bonferoni post-hoc 
test when significant interaction effect was reached (ie, P < .05). 
All statistical analyses were performed using SigmaPlot v11.0 
(Systat Software, London, UK).
Results
Effect of Morphine Withdrawal on Anxiety-Like, 
Depressive-Like, and Sociability Behaviors
Anxiety-Like Behaviors—We assessed anxiety-like behavior fol-
lowing the 7-day withdrawal from morphine using the EPM and 
open-field tests. Morphine-withdrawn animals spent signifi-
cantly less time in the open arms (P < .01; Figure 1a) and showed 
decreased time in the centre of the open-field arena (P < .01; 
Figure 1b) compared with saline-withdrawn animals.
Depressive-Like Behavior—Depressive-like behavior follow-
ing the 8-day withdrawal from morphine was assessed using 
the FST. Morphine-withdrawn animals showed significantly 
increased immobility time compared with saline-withdrawn 
animals (P < .05) (Figure 1c). Morphine-withdrawn mice needed 
significantly less time to reach the first immobility compared to 
saline-withdrawn mice (P < .01) (Figure 1d).
Sociability—The social preference in morphine-withdrawn 
mice was assessed using the 3-chambered sociability test follow-
ing 6 days of withdrawal. Saline-withdrawn mice exhibited a sig-
nificant preference for the chamber containing stranger mouse 
vs the empty chamber (P < .001) (Figure 1e). However, morphine-
withdrawn animals did not show any preference between the 
chamber containing the stranger mouse and the empty cham-
ber (P > .05; Figure 1e), demonstrating a lack of social preference. 
To directly demonstrate a lack of social preference of morphine 
withdrawn mice, we further analyzed the ratio of time spent in 
the “stranger” side vs time spent in the chamber containing the 
empty cage (social interaction ratio = time in stranger side/time 
in empty cage chamber). This analysis revealed a strong prefer-
ence for saline control mice to spend their time in the social 
chamber (2.14 ± 0.23 vs threshold of 1; 1-sample t test; P < .001), 
whereas morphine withdrawn mice did not show preference 
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for either of the 2 compartments (1.09 ± 0.09 vs threshold of 1; 
1-sample t test; P > .05).
Effect of Chronic Morphine Administration 
and Withdrawal on Body Mass and Relative 
Spleen Weight
Body weight was measured daily throughout the chronic mor-
phine administration and withdrawal paradigm. Chronic 
administration of morphine resulted in a lack of body weight 
gain compared with saline-treated animals, which reached 
statistical significance on day 5 (P < .01) (Figure  2a). Decreased 
weight gain persisted up to the second day of withdrawal (ie, day 
9) (day 6, P < .01; day 7, P < .001; day 8, P < .05; day 9, P < .01 vs saline 
controls) (Figure 2a).
We measured spleen weight in animals undergoing chronic 
morphine administration as well as withdrawal from morphine 
as an indicator of stress state of the animal. Indeed, decreased 
spleen weight has been previously associated with stress in 
rodents (Kyo et  al., 1999; Dominguez-Gerpe and Rey-Mendez, 
2001). Seven days of morphine administration did not change 
the relative spleen weight compared with the saline-treated 
animals. However, the 7-day withdrawal period from morphine 
administration induced a significant decrease in relative spleen 
weight compared with the saline-withdrawn controls (P < .001) 
(Figure 2b).
Effect of Chronic Morphine Administration and 
Withdrawal on mGlu5R Binding
Quantitative analysis of mGlu5R binding of morphine treated 
and withdrawal animals revealed a significant treatment 
effect in all the brain regions analyzed, including prelimbic 
cortex (F(1,20) =  21.370; P < .001), AcbC (F(1,22) =  94.810; P < .001), 
AcbSh (F(1,22) =  74.450; P < .001), lateral septum (F(1,20) =  37.160; 
P < .001), medial septum (F(1,22) =  37.310; P < .001), caudate puta-
men (F(1,20) =  61.160; P < .001), hippocampus (F(1,23) =  19.850; 
P < .001), amygdala (F(1,23) =  13.540; P < .01), thalamus (F(1,23) = 
13.170; P < .01), hypothalamus (F(1,23) =  13.60; P < .01), visual 
cortex (F(1,24) =  6.498; P < .05), ventral tegmental area (F(1,24) = 
10.490; P < .01), superficial grey (F(1,24) =  8.356; P < .01), and peri-
aqueductal grey (F(1,24) =  6.188; P < .05). A significant treatment x 
experimental phase interaction effect was observed in prelim-
bic cortex (F(1,20) = 9.612; P < .001), AcbC (F(1,22) = 21.760; P < .001), 
AcbSh (F(1,22) = 14.180; P < .01), lateral septum (F(1,20) = 20.114; 
P < .001), medial septum (F(1,22) = 10.120; p<0.01), caudate puta-
men (F(1,20) = 16.280; P < .001), thalamus (F(1,23) = 5.625; P < .05) and 
hypothalamus (F(1,23) = 4.330; P < .05). Following the 7-day mor-
phine administration, Bonferroni post-hoc analysis showed a 
significant increase in mGlu5R binding in the AcbC (P < .001), 
AcbSh (P < .01), and caudate putamen (P < .01) compared 
with the respective saline control (Figure  3a-b). Notably, the 
increase in mGlu5R binding observed in these regions was fur-
ther enhanced following the 7-day withdrawal period (chronic 
morphine compared with morphine withdrawal; P < .001) 
(Figure  3a-b). A  morphine-withdrawal effect was observed 
in all the brain regions analyzed (Figure  3a-b; prelimbic cor-
tex, P < .001; lateral septum, P < .001; medial septum, P < .001; 
thalamus, P < .001; hypothalamus, P < .001) compared with the 
respective saline-withdrawn controls. Compared with chronic 
morphine treatment, morphine withdrawal induced an upreg-
ulation of the mGlu5R binding in the prelimbic cortex (P < .01), 
medial septum (P < .01), lateral septum (P < .001), thalamus 
(P < .001), and hypothalamus (P < .01).
Figure 1. Depressive-like, anxiety-like behaviors, and sociability deficits following chronic protracted morphine withdrawal. Male C57BL/6J mice were treated with 
either saline or an escalating-dose morphine paradigm (2 x 20–100 mg/kg/d, i.p.) followed by 6 to 8 days withdrawal. (A) Open-arm time. (B) Open-arm entries. (C) 
Distance travelled in the elevated plus-maze (EPM) and (D) time in the center (percent of total) of an open field (OF) were measured to assess anxiety-like behaviors 
following 6 and 7 days of morphine withdrawal, respectively. (E) Sociability of morphine- and saline-withdrawn mice was also assessed using Crawley’s 3-chambered 
social approach test. (F) Immobility time was assessed in the forced-swim test (FST) following 7 days morphine withdrawal. Data are expressed as the mean ± SEM 
(n = 6/group). *P < .05, **P < .01, ***P < .001 (EPM, OF, and FST behaviors were scored using the Student’s t test; sociability behavior was analyzed using repeated-measures 
2-way ANOVA followed by Bonferroni post-hoc test).
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Effect of Acute Administration of the mGlu5R 
Antagonist MTEP on Morphine Withdrawal-Induced 
Depressive-Like Behaviors
Administration of MTEP 30 minutes prior to the FST reversed 
the increased immobility time induced by 8 days of morphine 
withdrawal in mice (Figure 4). Two-way ANOVA revealed a sig-
nificant main effect of treatment (F(1,19) =  10.230; P < .01) and 
pre-treatment x treatment interaction (F(1,23) = 4.66; P < .05). 
Morphine-withdrawn animals manifested increased immobility 
time in the FST, indicating the emergence of a depressive-like 
phenotype, while MTEP pretreatment abolished this behavioral 
deficit induced by morphine abstinence. MTEP administration 
did not alter immobility time of control/saline-treated animals 
(Figure 4).
Effects of MOPr Gene Deletion on mGlu5R Binding
Quantitative autoradiography of mGlu5 receptors from coro-
nal sections of fore-, mid-, and hind-brain mice showed a 
widespread distribution. The pattern of distribution of mGlu5 
receptors on MOPr knockout mice brains was identical to the 
wild-type mouse brains (Figure 5a). MOPr knockout brains had 
significantly increased mGlu5R binding in the AcbSh (P < .05), 
thalamus (P < .01), hypothalamus (P < .01), and amygdala (P < .05) 
(Figure 5b).
Regression analysis was carried out to determine if there 
was a correlation between the MOPr binding levels in regions 
of wild-type brains and percent change in mGlu5R binding in 
the regions analyzed of MOPr knockout mouse brains compared 
with MOPr binding levels derived from wild-type mice (Kitchen 
et al., 1997). Regression analysis revealed a significant correla-
tion (r = 0.7, n = 14, P < .01) (Figure 5c).
Discussion
The present study is the first, to our knowledge, to demonstrate 
a significant upregulation of mGlu5R throughout the whole brain 
in a mouse model of opioid-withdrawal characterized by emo-
tional impairment. We showed that a 6- to 8-day withdrawal 
period from chronic morphine administration induced anxiety-
like and depressive-like behaviors, and impaired sociability. 
Moreover, we provide evidence for direct effects of a MOPr sys-
tem manipulation on the mGlu5R in the AcbSh, thalamus, hypo-
thalamus, and amygdala, which are brain regions important in 
drug addiction and emotional regulation (Bossert et  al., 2007; 
Chaudhri et al., 2010; Zanos et al., 2014).
We first characterized a mouse model of opioid withdrawal, 
which mimics the negative affective state displayed by opioid 
addicts undergoing abstinence following detoxification (Martin 
and Jasinski, 1969; Jaffe, 1990; Nunes et al., 2004; Peles et al., 2007; 
Veilleux et al., 2010). We have previously shown, using the same 
chronic morphine administration and withdrawal protocol, that 
physical withdrawal symptoms associated with acute morphine 
withdrawal (ie, withdrawal jumping, increased defecation, and 
changes in body weight) disappear following a 7-day abstinence 
period (Goeldner et al., 2011; Zanos et al., 2014); however, emo-
tional impairment is evident, highlighting the translational 
validity of our mouse model. This impairment has been reported 
to be even more evident after 4 weeks of abstinence (Goeldner 
et al., 2011) and was accompanied by significant alterations of 
gene expression in the extended amygdala (Le Merrer et  al., 
2012). In the present study, decrease in relative spleen weight 
was observed in 7-day-withdrawn animals, further supporting 
a stress-related phenotype. Decreased spleen weight has been 
previously correlated with higher levels of emotional stress in 
rodents (Kyo et  al., 1999; Dominguez-Gerpe and Rey-Mendez, 
2001).
The emotional impairment observed in the present study 
was accompanied by an abundant increase in mGlu5R bind-
ing in the brain. These findings are supported by previous 
data showing that chronic morphine administration induces 
a dose-dependent upregulation of mGlu5R immunoreactivity 
in the spinal cord in mice (Narita et  al., 2005). An increase in 
the expression of mGlu5R protein was also found in the spinal 
cord of morphine-tolerant rats (Liu et al., 2009) and the ventral 
pallidum of morphine-dependent rats (Herrold et  al., 2013). 
Interestingly, administration of the mGlu5R antagonist MPEP 
prevented the development of morphine tolerance by specifi-
cally preventing the increased expression of mGlu5R protein in 
the spinal cord (Liu et al., 2009), supporting a biological/behav-
ioral relevance of these mGlu5R alterations. However, this is first 
study to demonstrate profound alterations of mGlu5R binding in 
the brain following opioid withdrawal.
Although the molecular mechanism underlining the chronic 
morphine/withdrawal induced upregulation of mGlu5R is not 
clear, one can speculate on various potential mechanisms. First, 
there is evidence to suggest that mGlu5R upregulation may be 
a result of a compensatory neuroadaptive response to a sup-
pression of glutamate neurotransmission during morphine 
withdrawal. Indeed there is evidence showing that chronic opi-
oid administration suppresses glutamate neurotransmission 
Figure  2. Effects of chronic morphine administration and withdrawal on body 
weight and relative spleen weight. Male C57BL/6J mice were treated with either 
saline or escalating-dose morphine paradigm (2 x 20–100 mg/kg/d, i.p.) followed 
by a 7-day withdrawal period. (A) Changes in body weight and (B) relative spleen 
weight during chronic morphine or saline administration and withdrawal. Data are 
expressed as the mean ± SEM (n = 6–12/group). *P < .05, **P < .01, ***P < .001 vs saline 
control (repeated-measures 2-way ANOVA followed by Bonferroni post-hoc test).  by guest on February 25, 2016
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in the central nervous system (Manzoni and Williams, 1999; 
Xu et al., 2003). This hypoglutamatergic state may thus in turn 
induce a compensatory increase in mGlu5R to enhance gluta-
matergic synaptic transmission. It has been postulated that 
such a mechanism may at least partly be responsible for the 
suppression of tolerance to spinal antinociception induced by 
morphine treatment (Suzuki et  al., 2006). Another potential 
mechanism may involve chronic morphine-induced allosteric 
modulation of mGlu5R. Indeed, Schroder et  al. (2009) provided 
compelling evidence that this may be the case in vitro. They 
Figure 3. Morphine withdrawal increases metabotropic glutamate receptor 5 (mGlu5R) binding in the brain. (A) Representative autoradiograms of 10 μΜ [
3H]-2-methyl-
6-([3,5-3H] phenylethynl) pyridine ([3H]MPEP) binding to mGlu5R in coronal brain sections of mice undergoing chronic saline or morphine administration and 7-day 
withdrawal. Autoradiograms of brain sections were taken at the level of prefrontal cortex (Bregma: 2.34 mm; first row), striatum (Bregma: 0.62 mm; second row), 
thalamus (Bregma: -1.82 mm; third row), and ventral tegmental area (Bregma: -3.40 mm; fourth row). Binding levels are represented using a pseudocolor interpretation 
of black and white film images in fmol/mg of tissue equivalent. (B) Quantitative mGlu5R binding in the brain of mice subjected to morphine administration and with-
drawal. Data are expressed as the mean ± SEM (n = 6–7/group). *P < .05, **P < .01, ***P < .001 (2-way ANOVA followed by Bonferroni post-hoc test per brain region).
Figure 4. Pretreatment with the metabotropic glutamate receptor 5 (mGlu5R), 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP), prevents morphine abstinence-induced 
depressive-like behaviors. Male C57BL/6J mice were treated with either saline or escalating-dose morphine paradigm (2 x 20–100 mg/kg/d, i.p.) followed by a 7-day 
withdrawal period. Administration of the mGlu5R antagonist, MTEP, abolished the depressive-like behaviors induced by morphine withdrawal in the forced-swim test 
(FST). Data are expressed as the mean ± SEM (n = 5–6/group). *P < .05, **P < .01 (2-way ANOVA followed by Bonferroni post-hoc test).
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found that MPEP binding site affinity and Bmax for mGlu5R is 
significantly increased in MOPr- mGlu5R coexpressing cells vs 
mGlu5R-only expressing cells, suggesting that the interaction 
between MOPr and mGlu5R can profoundly alter the conforma-
tion of mGlu5R. In our study, it cannot be determined if chronic 
morphine/withdrawal alters the affinity or Bmax of mGlu5R or 
both, but based on the evidence of Schroder et al. (2009), it is 
tempting to speculate that the profound upregulation of mGlu5R 
in response to chronic morphine treatment could be caused by 
a change in mGlu5R affinity and/or decrease in receptor inter-
nalization. Finally, there is increasing evidence suggesting the 
existence of MOPr-mGlu5R heterodimerization that may at 
least partly explain the profound changes of mGlu5R following 
chronic morphine treatment/withdrawal. Indeed, studies show-
ing that desensitization, phosphorylation and internalization 
of MOPr are influenced by mGlu5R modulation (Schroder et al., 
2009), further suggest the presence of MOPr-mGlu5R heterodi-
mers. Furthermore, it has been demonstrated that targeting 
the putative MOPr-mGlu5R heteromer using a bivalent ligand 
containing MOPr agonist and mGlu5R antagonist is effective in 
decreasing inflammatory and chronic cancer pain (Akgun et al., 
2013; Smeester et al., 2014).
To directly assess the relation between the observed 
upregulation of the mGlu5R and the behavioral deficits of 
morphine-withdrawn mice, we tested the effect of an mGlu5R 
receptor antagonist, MTEP, on morphine abstinence-induced 
depressive-like behavior in the FST. The complete reversal of 
morphine abstinence-associated depressive-like behavior fol-
lowing administration of MTEP clearly indicates a key role for 
mGlu5R in the manifestation of the emotional consequences of 
opioid abstinence and is highly suggestive of a causal relation-
ship between the evident mGlu5R upregulation in the brain of 
morphine-withdrawn mice and the observed emotional defi-
cits. This finding is consistent with the antidepressant effect 
of mGlu5R antagonists in rodent stress models (Li et al., 2006; 
Belozertseva et al., 2007). It is also likely that mGlu5R may also 
be involved in the anxiogenic and social deficit consequences 
of opioid abstinence, as mGlu5R antagonism was shown to 
reverse ethanol withdrawal-induced anxiety (Kumar et al., 2013) 
and rescue social deficits observed in a mouse model of autism 
(Silverman et al., 2012).
To further explore possible effects of a manipulated MOPr sys-
tem on the mGlu5R in the brain, we assessed the effect of MOPr 
gene deletion on mGlu5R binding with the use of MOPr knockout 
mice, which are characterized by certain behavioral phenotypic 
and MOPr signalling characteristics that are reminiscent of our 
model of morphine abstinence. Notably, similar to our morphine-
withdrawal mouse model, MOPr knockout mice display deficits 
Figure 5. Metabotropic glutamate receptor 5 (mGlu5R) binding in the brain of mice lacking the μ-opioid receptor (MOPr) gene. (A) Representative autoradiograms of 
10 μΜ [3H]-2-methyl-6-([3,5-3H] phenylethynl) pyridine ([3H]MPEP) binding to mGlu5R in coronal brain sections of wild-type (WT) and MOPr knockout (MOPr
-/-) mice. 
Autoradiograms of brain sections were taken at the level of striatum (Bregma: 0.62 mm; first row) and thalamus (Bregma: -1.82 mm; second row). Representative autora-
diograms for nonspecific binding (NSB) are shown (far right column). Binding levels are represented using a pseudocolor interpretation of black and white film images 
in fmol/mg of tissue equivalent. (B) Quantitative mGlu5R binding. Data are expressed as the mean ± SEM (n = 7/group). *P < .05, **P < .01, ***P < .001 vs wild-type control 
(Student’s t-test per brain region). (C) Correlation analysis between percentage change in mGlu5R binding in MOPr knockout mice and MOPr binding in wild-type mice. 
(n = 14; r = 0.7; P < .01).
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in social behavior and emotional impairment (Becker et al., 2014). 
Furthermore, consistent with the MOPr KO mouse model, where 
MOPr are completely absent, repeated administration of mor-
phine, which primarily acts on MOPr, is well known to induce a 
significant reduction in MOPr activation of G-protein in the brain 
of rats (Sim et al., 1996) and thus lead to MOPr desensitization 
that persists during withdrawal (Ingram et al., 2007). Therefore, it 
is not perhaps surprising that similar alterations of mGlu5R bind-
ing in the same direction are observed in brain regions of MOPr 
KO mice and chronically morphine-treated/-withdrawn mice, 
both of which are models of reduced MOPr activity.
Our data demonstrate a marked mGlu5R upregulation in MOPr-
null mice in brain regions that are well known to be rich in MOPr, 
such as the AcbSh, thalamus, hypothalamus, and amygdala, sup-
porting the plausible existence of brain region-specific mGlu5R-
MOPr interactions; however, in the present study, direct receptor 
interactions have not been investigated. These brain regions are 
involved in the regulation of drug-induced reward (Bosser et al., 
2007; Chaudhri et al., 2010) and withdrawal-induced emotional 
deficits (Zanos et al., 2014), as well as reinstatement (Georgiou 
et al., 2015). Our data add to the existing evidence for an asso-
ciation between the central mGlu5R and MOP systems (Schroder 
et al., 2009; Akgun et al., 2013; Smeester et al., 2014). Indirect evi-
dence further suggests a possible modulatory inter-play between 
mGlu5R and MOPr systems in the striatum to regulate opioid-
related behaviors, since intra-Acb administration of an mGlu5R 
antagonist attenuated the acquisition of morphine CPP (Roohi 
et al., 2014), and intra-AcbSh, but not intra-AcbC, administration of 
an mGlu5R antagonist attenuated both cue- and priming-induced 
reinstatement of heroin-seeking behavior in rats (Lou et al., 2014). 
The exact neurobiological mechanism underlying the observed 
mGlu5R upregulation in the MOPr knockout mice remains unclear, 
since glutamate content and/or release in the brain of MOPr 
knockout mice have not been evaluated so far. If glutamatergic 
neurotransmission in these mice is generally reduced, an upregu-
lation of the mGlu5R may represent a compensatory mechanism 
to counteract the neuronal responses to decreased glutamate 
levels; however, in the present study we observed region-specific 
upregulation of mGlu5R in these mice and not a global effect, 
which indicates that the possibility of a direct molecular interac-
tion between mGlu5R and MOPr in specific brain regions is more 
likely to exist. Indeed, GPCRs, including mGlu5R and MOPr, are 
capable of forming heterodimers, and it has been shown that this 
physical association can modulate receptor binding and function 
(Schroder et  al., 2009; Smeester et  al., 2014). If dimeric interac-
tions exist between these 2 systems, the lack of MOPr may result 
in alterations of mGlu5R pharmacology in brain regions where 
the 2 receptors physically interact. Although this possibility is 
only speculative at present, it deserves further investigation.
Taken together, our findings showed that 6 to 8 days of mor-
phine withdrawal induces emotional deficits in mice, which is 
concomitant with marked neuroadaptations in the mGlu5R sys-
tem in the brain. These results suggest a possible involvement 
of the mGlu5R in the modulation of comorbid behavioral impair-
ment during opioid abstinence and point toward targeting this 
system for the development of novel pharmacotherapies for 
opioid addiction. Moreover, our data suggest a direct inter-play 
between mGlu5R and MOPr in brain regions associated with drug 
addiction, reward, and emotions.
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